Staccato Loxapine Pulmonary Safety in Patients With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Asthma
Interventions
DRUG

Inhaled loxapine @ 0 & 10 h

10 mg, 2 doses, 10 hours apart

DRUG

Inhaled placebo @ 2 & 10 hours

placebo, 2 doses, 10 hours apart

Trial Locations (1)

92123

Allergy and Asthma Medical Group & Research Center, A.P.C., San Diego

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY

NCT00890175 - Staccato Loxapine Pulmonary Safety in Patients With Asthma | Biotech Hunter | Biotech Hunter